Georgia lawmakers and medical cannabis advocates gathered at Mercer University in Macon to debate broadening the state's decade-old medical cannabis program. The meeting signals a potential shift toward greater access for patients, amid calls to increase THC potency in approved oils. With only three production facilities serving 33,000 patients, advocates argue the current restrictions leave many underserved.
Cautious Approach Shapes Policy Discussions
Representative Mark Newton emphasized the need for thorough study before any expansion. Georgia legalized medical cannabis in 2015, yet the program remains limited to low-THC oils. Newton stressed careful policymaking to avoid hasty changes, reflecting lawmakers' wariness after nearly ten years of operation.
Proven Benefits Drive Push for Change
Representative Robert Dickey highlighted the program's value for patients in need. Limited medical research stems from cannabis's federal illegality, but Dickey sees substantial potential to aid more Georgians. The state now supports over 10 dispensaries, though production lags with just three facilities, including Fine Fettle in Macon.
Industry Leaders Seek Stronger Products
Judson Hill, president of Fine Fettle, urged lawmakers to raise THC percentages. Georgia's low-THC oil program falls short compared to 40 other states with robust medical cannabis frameworks. Hill argued that current limits deny patients essential product strength and variety, hindering effective treatment.
Broader Implications for Patient Care
Georgia's program operates in a patchwork national landscape where most states permit medical cannabis. Restrictions on THC content trace back to initial legalization, prioritizing minimal psychoactivity while aiming for therapeutic relief. Expansion could align Georgia with peers, potentially easing symptoms for conditions like epilepsy and chronic pain, though federal barriers continue to constrain research and production scale.
